$AMGN News Article - Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
https://marketwirenews.com/news-releases/amge...50678.html